Gain Therapeutics, INC 8-K filings

Gain Therapeutics announced FDA IND acceptance for rexaceract's Phase 2 trial and reported Q2 2026 financial results, highlighting pipeline progress despite a net loss.

Gain Therapeutics announced its cash and cash equivalents are projected to fund operations into Q2 2027, with key clinical trial milestones expected in late 2026.

Gain Therapeutics announced the FDA has authorized its Investigational New Drug application for GT-02287, paving the way for Phase 2 clinical development in Parkinson's disease.

Gain Therapeutics shareholders re-elected seven directors and ratified the appointment of Ernst & Young AG as the company's independent auditor.

Gain Therapeutics presented interim clinical and biomarker data from its Phase 1b study of GT-02287 for Parkinson's disease, showing promising tolerability and potential benefits.

Gain Therapeutics reports Q1 2026 financial results, highlighting progress in its Parkinson's disease candidate GT-02287 and a new lead compound GT-04686.

Gain Therapeutics announced its 2025 financial results and significant clinical and preclinical progress for its Parkinson's disease drug candidates, GT-02287 and GT-04686.

Gain Therapeutics presented encouraging Phase 1b clinical and preclinical data for its Parkinson's disease drug candidates GT-02287 and GT-04686 at the AD/PD 2026 conference.

Gain Therapeutics announced positive Phase 1b biomarker and clinical data for its lead Parkinson's disease candidate, GT-02287, paving the way for Phase 2 initiation in 2H 2026.

Gain Therapeutics, Inc. announced positive exploratory endpoint results from its Phase 1b clinical study of GT-02287 for Parkinson's Disease, showing significant reduction in a key biomarker.

Gain Therapeutics, Inc. filed a prospectus supplement to offer and sell up to $35.5 million of common stock through an at-the-market offering program.

Gain Therapeutics announced its third-quarter 2025 financial results and provided an encouraging update on its Phase 1b clinical study for GT-02287 in Parkinson's Disease.

Gain Therapeutics hosted a Key Opinion Leader event to discuss emerging data from its Phase 1b study of GT-02287 for Parkinson's Disease, highlighting safety and initial efficacy trends.

Gain Therapeutics, Inc. announced the immediate resignation of Eric Richman from its Board of Directors, effective October 6, 2025, with no reported disagreements.

Gain Therapeutics announced preliminary Phase 1b clinical data for GT-02287 in Parkinson's disease, demonstrating safety, tolerability, and early signs of disease-slowing effects.

Gain Therapeutics announced early completion of Phase 1b Parkinson's disease study enrollment and reported reduced Q2 2025 net loss, bolstered by a recent $7.1 million public offering.

A clinical-stage biotechnology company has priced a public offering of common stock and warrants, aiming to raise approximately $7.0 million to fund its clinical and nonclinical development programs.

Gain Therapeutics, Inc. announced accelerated biomarker analysis for its GT-02287 Parkinson's disease Phase 1b study, with full 90-day results now expected in Q4 2025, despite an initial protocol delay.

Gain Therapeutics, Inc. announced that its shareholders approved an increase in authorized common stock from 50 million to 100 million shares, alongside the election of directors and ratification of its auditor, at the annual meeting held on June 24, 2025.

Gain Therapeutics announced its Q1 2025 financial results, provided a corporate update, and expects first biomarker analysis from Phase 1b study of GT-02287 in Parkinson's Disease mid-2025.

Gain Therapeutics presents promising preclinical data and the design of its Phase 1b clinical study for GT-02287, a potential disease-modifying treatment for Parkinson's disease.

Gain Therapeutics reports financial results for the fourth quarter and year ended December 31, 2024, and provides a corporate update, highlighting progress in its Parkinson's disease program.

Gain Therapeutics announces progress in its GT-02287 Parkinson's disease program, including the initiation of a Phase 1b clinical trial and plans for future development.

Gain Therapeutics was notified by Nasdaq that it did not meet the minimum Market Value of Listed Securities (MVLS) requirement, but has since regained compliance.

Gain Therapeutics has appointed Gene Mack as its new CEO and a member of the board, while also naming Gianluca Fuggetta as Principal Financial Officer.

Gain Therapeutics has announced the approval to begin a Phase 1b clinical trial in Australia for their lead drug candidate, GT-02287, targeting Parkinson's disease.

Gain Therapeutics announced positive Phase 1 clinical trial results for their lead drug candidate, GT-02287, and provided a business update along with their third quarter 2024 financial results.

Gain Therapeutics has successfully regained compliance with Nasdaq's minimum market value requirement, resolving a previous non-compliance issue.

Gain Therapeutics has released preclinical data showing its drug candidate, GT-02287, demonstrates disease-modifying potential in Parkinson's disease models, including sustained benefits after treatment withdrawal.

Gain Therapeutics has entered into an agreement with Oppenheimer & Co. to sell up to $50 million of its common stock through an at-the-market offering program.